Cold storage challenges could hamper distribution of Pfizer, Moderna COVID-19 vaccines - Fauci

(Reuters) - Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, on Wednesday said it would be challenging to distribute vaccines that use messenger RNA based technology in developing countries, owing to their cold storage requirements

Reuters November 12, 2020 00:06:22 IST
Cold storage challenges could hamper distribution of Pfizer, Moderna COVID-19 vaccines - Fauci

COVID-19 vaccines - Fauci" src="https://images.firstpost.com/wp-content/uploads/reuters/11-2020/12/2020-11-11T164654Z_1_LYNXMPEGAA1E2_RTROPTP_2_HEALTH-CORONAVIRUS-USA.jpg" alt="Cold storage challenges could hamper distribution of Pfizer Moderna COVID19 vaccines Fauci" width="300" height="225" />

(Reuters) - Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, on Wednesday said it would be challenging to distribute vaccines that use messenger RNA based technology in developing countries, owing to their cold storage requirements.

The comments come days after Pfizer Inc said its experimental COVID-19 vaccine is more than 90% effective based on initial trial results and that it expects to file for U.S. emergency authorization this month.

The vaccine candidate uses synthetic messenger RNA to activate the immune system against the virus and needs to be kept at minus 70 degrees Celsius (-94 F) or below.

"It does have cold-chain challenges as it were. In a country like the UK and the United States we can address them and it still would be challenging. But, probably much more challenging in countries in the developing world," Fauci said at the Financial Times' global pharmaceutical and biotechnology conference.

Moderna Inc's experimental vaccine, which is on track to report early data from a late-stage trial later this month, also uses mRNA technology and needs to be stored at minus 20 degrees Celsius (-4 F).

"That's the reason why when we put together our plan ... we want to have a diversity of what we call vaccine platforms. It is not just mRNA ... there are three separate platforms that are being looked at in the United States," Fauci said.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Chris Reese)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

U.S. job openings rise slightly in September
Business

U.S. job openings rise slightly in September

WASHINGTON (Reuters) - U.S. job openings increased moderately in September and layoffs appeared to abate, pointing to a gradual labor market recovery from the COVID-19 pandemic.

Central bankers seek new role in brave new world
Business

Central bankers seek new role in brave new world

By Balazs Koranyi and Francesco Canepa FRANKFURT (Reuters) - Taking a break from fighting the coronavirus crisis, the world's top central bankers will attempt to resolve the existential questions of their profession this week as they tune into the European Central Bank's annual policy symposium. Having struggled to lift anaemic inflation for years, officials including the heads of the ECB, the U.S. Federal Reserve and the Bank of England will attempt to figure out why monetary policy is not working as it used to and what new role they must play in a changed world - be it fighting inequality or climate change.

Asian stocks extend gains as vaccine hopes support global reopening
Business

Asian stocks extend gains as vaccine hopes support global reopening

By Lawrence Delevingne BOSTON (Reuters) - Asian shares rose on Wednesday as hopes for a successful coronavirus vaccine lifted expectations of a swift reopening of the global economy, which would help the region's heavily trade-dependent markets.